Sign Out
Menotrophin (Gynogen HP) is a drug that should only be used by physicians who are thoroughly familiar with infertility problems.
Overstimulation of the Ovary During Menotrophin Therapy: Ovarian Enlargement: Mild to moderate uncomplicated ovarian enlargement which may be accompanied by abdominal distention or abdominal pain occurs in approximately 5 to 10 % of women treated with menotrophins and hCG, and generally regresses without treatment within two or three weeks. The lowest dose consistent with expectation of good results and careful monitoring of ovarian response can further minimized the risk of over stimulation. If the ovaries are abnormally enlarged on the last day of Menotrophin (Gynogen HP) therapy, hCG should not be administered in this course of treatment; this will reduce the chances of development of Ovarian Hyperstimulation Syndrome (OHSS).
Continue with Google